Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read MorePosted by Edisource Vendor | Sep 3, 2025 | Lung Cancer |
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read MorePosted by Edisource Vendor | Aug 18, 2025 | Immunoassay Reagents & test Kits |
UK diagnostics developer signs with multi-site laboratory group to scale commercial launch of early-stage lung cancer biomarker test across the United States.
Read MorePosted by Chris Wolski | May 20, 2025 | Lung Cancer |
The FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MorePosted by Chris Wolski | Mar 20, 2025 | Lung Cancer |
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Read MorePosted by Chris Wolski | Feb 6, 2025 | Lung Cancer |
Scientists have developed a low-cost, fast-response sensor capable of detecting lung cancer biomarkers from a blood sample in just 40 minutes.
Read More